Search fresh public links, source activity, and post angles for Car-T.
Fresh curated links around CAR-T are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
In the rapidly evolving landscape of immunotherapy, CAR-T cell therapy has emerged as a beacon of hope for treating various malignancies, particularly hematologic cancers. A ground...
In a groundbreaking advancement poised to redefine the landscape of immunotherapy, researchers have unveiled a novel strategy employing allogeneic CD19 CAR T cells augmented with a...
_on_a_T-cell_is_binding_to_a_molecule_on_a_cancer_-_Alpha_Tauri_3D_Graphics_M1_dc8762afeaee4937ad644739f274c7a5-620x480.jpg)
Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of hematologic malignancies, offering durable responses for patients with otherwise refractory dis...
Chimeric antigen receptor (CAR) T-cell therapy, initially developed for hematologic malignancies, engineers autologous T cells to eliminate pathogenic immune populations and aims t...
Scientists developed a cytokine-armored CAR T-cell therapy that helps the immune system better attack aggressive brain tumors in mice, which they paired with a CAR T strategy targe...
The scalable biomanufacturing of autologous products to supply thousands of patients per year can potentially be achieved with minimal capital investment and a low cost of goods. T...
In a groundbreaking study that could redefine the landscape of cellular immunotherapy, researchers have delved deep into the molecular and cellular dynamics underpinning CAR-T cell...
There has been a swing towards in vivo CAR-T therapies lately, as big pharmas sign acquisition deals and new therapies hit the clinic. The post CAR-T cell therapies going in vivo ...
In vivo engineering strategies promise faster, scalable cell therapies and a streamlined path from discovery to clinical development. The post Rewriting CAR T From Within appeared...
As CAR T moves into complex in vivo systems, defined antibodies and consistent reagents safeguard early biological signals and translational insight. The post Signal or Noise? Deco...
It’s been more than four years since Novartis shook up the CAR-T space with its T-Charge platform. But that’s a lifetime in the fast-moving world of cell therapies.
Cema-cel eradicated minimal residual disease in seven of 12 patients, compared to two of 12 participants in the observational control arm.
Early results presented at AACR show that a novel KIR‑CAR T therapy demonstrates safety and efficacy in solid tumors, pointing to a new strategy for addressing T cell exhaustion an...
In a groundbreaking advancement poised to redefine cancer immunotherapy, researchers have surmounted one of the most formidable challenges in cell-based therapies: the direct genet...
No medicines have been approved for stiff person syndrome yet. However, Kyverna Therapeutics' CAR-T cell therapy is headed towards approval. The post CAR-T therapy for stiff perso...
An immunotherapy typically used in advanced stages of multiple myeloma may be effective against an early form of the disease known as smoldering myeloma—offering a potential new op...
Initial results from a high-stakes trial indicate the biotech may have finally found a niche in lymphoma care for a donor-derived cell therapy.
SHANGHAI, May 24, 2026 /PRNewswire/ -- A 36-year-old Pakistani patient has achieved encouraging early recovery after receiving personalized CAR-T immunotherapy at Jiahui Internatio...
A woman with three different autoimmune conditions had all of them treated simultaneously by genetically modifying her immune cells to kill off the rogue ones causing problems
For the first time, scientists have used a cutting-edge cell therapy called CAR-T to treat a patient with three different life-threatening autoimmune diseases that had resisted yea...
The partnership will automate manufacturing and quality control of ProT-096, ProTgen’s personalized progenitor T-cell therapy for refractory leukemia and other hematologic malignan...
VMPLNew Delhi [India], April 29: A patient from Mauritius with relapsed aggressive non-Hodgkin's lymphoma travelled to India for an indigenously manufactured CAR-T cell therapy by...
A new study reveals a possible way to make CAR T-cell therapy more durable and effective by targeting a single gene-regulating protein. CAR T-cell therapy is widely seen as a break...
Nine years after wowing the audience at the American Society of Clinical Oncology annual meeting with a CAR-T candidate that would become Carvykti—now the world’s most successful c...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.